Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1764) · e79-e80
DOI: 10.58347/tml.2026.1754f ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.
Abstract (Originalsprache)
Relacorilant (Lifyorli – Corcept Therapeutics), an oral first-in-class glucocorticoid receptor antagonist, has been approved by the FDA for use in combination with nab-paclitaxel (Abraxane, and generics) for treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who received 1-3 prior lines of systemic therapy, one of which included bevacizumab (Avastin, and others).
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. The Medical Letter on Drugs and Therapeutics, 68(1764), e79-e80. https://doi.org/10.58347/tml.2026.1754f
Vancouver
Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. The Medical Letter on Drugs and Therapeutics. 2026;68(1764):e79-e80. doi:10.58347/tml.2026.1754f
BibTeX
@article{euvimed2026,
title = {Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1764},
pages = {e79--e80},
doi = {10.58347/tml.2026.1754f}
}
EUVIMED